questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for NHS use; and whether he plans to review the CAR‑T delivery tariff to ensure continued access to treatments.
answerText: The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cance...
heading: Blood Cancer: Medical Treatments